Terri L. Parker

2.1k total citations
38 papers, 458 citations indexed

About

Terri L. Parker is a scholar working on Hematology, Genetics and Dermatology. According to data from OpenAlex, Terri L. Parker has authored 38 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 10 papers in Genetics and 9 papers in Dermatology. Recurrent topics in Terri L. Parker's work include Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Lymphoma Diagnosis and Treatment (7 papers). Terri L. Parker is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Lymphoma Diagnosis and Treatment (7 papers). Terri L. Parker collaborates with scholars based in United States, Italy and Australia. Terri L. Parker's co-authors include Noffar Bar, Natalia Neparidze, Matthew P. Strout, Kavita M. Dhodapkar, Terrie E. Taylor, R.H.S. Gregson, Giuseppe Maria Milano, David Walker, Timothy Ritzmann and Charlotte Benson and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Terri L. Parker

34 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Terri L. Parker United States 11 203 159 135 132 120 38 458
M. Qazilbash United States 11 374 1.8× 257 1.6× 154 1.1× 180 1.4× 83 0.7× 22 602
Sarah Witt United States 5 213 1.0× 135 0.8× 33 0.2× 96 0.7× 130 1.1× 6 560
Bénédicte Deau France 12 96 0.5× 169 1.1× 72 0.5× 118 0.9× 100 0.8× 43 476
László Gopcsa Hungary 13 132 0.7× 92 0.6× 79 0.6× 100 0.8× 53 0.4× 44 339
Tommasina Perrone Italy 14 186 0.9× 183 1.2× 65 0.5× 154 1.2× 85 0.7× 41 562
Salman Fazal United States 12 394 1.9× 140 0.9× 192 1.4× 113 0.9× 320 2.7× 51 653
Xavier Cahu France 12 221 1.1× 146 0.9× 51 0.4× 80 0.6× 114 0.9× 22 414
Sebastian Meerwein United States 8 299 1.5× 193 1.2× 28 0.2× 158 1.2× 126 1.1× 23 675
Myrna Cardiel United States 3 304 1.5× 157 1.0× 29 0.2× 162 1.2× 157 1.3× 5 711
Henry Januszewicz Australia 15 126 0.6× 191 1.2× 115 0.9× 108 0.8× 102 0.8× 23 644

Countries citing papers authored by Terri L. Parker

Since Specialization
Citations

This map shows the geographic impact of Terri L. Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terri L. Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terri L. Parker more than expected).

Fields of papers citing papers by Terri L. Parker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terri L. Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terri L. Parker. The network helps show where Terri L. Parker may publish in the future.

Co-authorship network of co-authors of Terri L. Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Terri L. Parker. A scholar is included among the top collaborators of Terri L. Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terri L. Parker. Terri L. Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Parker, Terri L., Vaishali Sanchorawala, Heather Landau, et al.. (2025). Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702). Blood. 146(21). 2507–2516.
3.
Chen, Yang, Maureen Canavan, Nina Kim, et al.. (2024). Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal of Palliative Medicine. 27(7). 879–887. 1 indexed citations
4.
5.
Parker, Terri L., Adam Rosenthal, Vaishali Sanchorawala, et al.. (2024). Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). Blood. 144(Supplement 1). 3378–3378.
6.
Li, Fangyong, Terri L. Parker, Noffar Bar, et al.. (2024). Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.. Journal of Clinical Oncology. 42(16_suppl). 7559–7559. 1 indexed citations
7.
8.
Patel, Kishan, Terri L. Parker, Mengyang Di, et al.. (2021). Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & lymphoma. 62(11). 2777–2784. 6 indexed citations
9.
Patel, Kishan, Smith Giri, Terri L. Parker, et al.. (2021). Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal of Clinical Oncology. 39(10). 1119–1128. 28 indexed citations
10.
11.
Parker, Terri L., Adam Rosenthal, Vaishali Sanchorawala, et al.. (2020). A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood. 136(Supplement 1). 20–21. 17 indexed citations
12.
Bailur, Jithendra Kini, Samuel S. McCachren, Deon B. Doxie, et al.. (2019). Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. JCI Insight. 4(11). 117 indexed citations
13.
Bailur, Jithendra Kini, Sameet Mehta, Lin Zhang, et al.. (2017). Early Enrichment and Subsequent Dysfunction of Marrow ILC Subsets in Monoclonal Gammopathy: Target for IMiD Therapy. Blood. 130. 4370. 2 indexed citations
14.
15.
Foss, Francine M., Terri L. Parker, & Anlong Li. (2016). Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate.. Journal of Clinical Oncology. 34(15_suppl). 7558–7558. 1 indexed citations
16.
Lee, Eun‐Ju, Daniel Dykas, A. Bale, et al.. (2015). Whole Exome Sequencing in Evaluation of Thrombophilia: A Novel 33-Gene Panel. Blood. 126(23). 3529–3529. 1 indexed citations
17.
Parker, Terri L., Lisa Barbarotta, Michael Girardi, & Francine M. Foss. (2012). Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood. 120(21). 3660–3660. 1 indexed citations
18.
Parker, Terri L. & Matthew P. Strout. (2011). Chronic lymphocytic leukemia: prognostic factors and impact on treatment.. PubMed. 11(57). 115–23. 30 indexed citations
19.
Taylor, Terrie E., T. Jaspan, Giuseppe Maria Milano, et al.. (2008). Radiological classification of optic pathway gliomas: experience of a modified functional classification system. British Journal of Radiology. 81(970). 761–766. 91 indexed citations
20.
Hull, Alan R., Richard Dickerman, Clarke E. Atkins, et al.. (1979). Comparisons of dialysis and transplant results from one center.. PubMed. 11(1). 125–6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Qazilbash Breakdown of academic impact, for papers by Sarah Witt Breakdown of academic impact, for papers by Bénédicte Deau Breakdown of academic impact, for papers by László Gopcsa Breakdown of academic impact, for papers by Tommasina Perrone Breakdown of academic impact, for papers by Salman Fazal Breakdown of academic impact, for papers by Xavier Cahu Breakdown of academic impact, for papers by Sebastian Meerwein Breakdown of academic impact, for papers by Myrna Cardiel Breakdown of academic impact, for papers by Henry Januszewicz
Rankless by CCL
2026